Get the Stockscreener App
17.14
4.13%
0.68
After Hours:
16.85
-0.29
-1.69%
Kalvista Pharmaceuticals Inc stock is traded at $17.14, with a volume of 1.69M.
It is up +4.13% in the last 24 hours and up +8.76% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$16.46
Open:
$17.17
24h Volume:
1.69M
Relative Volume:
1.72
Market Cap:
$866.36M
Revenue:
$15.12M
Net Income/Loss:
$-210.31M
P/E Ratio:
-4.2714
EPS:
-4.0127
Net Cash Flow:
$-168.39M
1W Performance:
+10.65%
1M Performance:
+8.76%
6M Performance:
+41.71%
1Y Performance:
+37.12%
1-Day Range:
$16.44
$17.66
1-Week Range:
$15.09
$17.66
52-Week Range:
$9.235
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
17.14 | 831.99M | 15.12M | -210.31M | -168.39M | -4.0127 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Reiterated | Needham | Buy |
| Jan-06-26 | Reiterated | Needham | Buy |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Kalvista stock price target raised to $42 by Stifel on Ekterly demand - Investing.com
Jefferies reiterates Kalvista stock rating on strong Ekterly sales - Investing.com
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Raises Target Price to $42 - Moomoo
EKTERLY launches; KalVista (KALV) secures multi‑market approvals and $122M financing - Stock Titan
KalVista Pharmaceuticals Inc (KALV) Q4 2025 Earnings Call Highlights: Strong Launch of EKTERLY ... By GuruFocus - Investing.com Canada
KalVista Pharmaceuticals Inc (KALV) Q4 2025 Earnings Call Highli - GuruFocus
Published on: 2026-03-25 22:56:15 - baoquankhu1.vn
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update - BioSpace
KalVista Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Leerink reiterates Kalvista stock rating on strong Ekterly sales - Investing.com
KalVista reports $49.1M in EKTERLY sales for eight months - Investing.com
KALV Projects Profitability with $300.2 Million in Cash Reserves - GuruFocus
Earnings Flash (KALV) KalVista Pharmaceuticals Posts Eight Months Net Loss $2.03 a Share - marketscreener.com
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Business Wire
Profit Recap: What are KalVista Pharmaceuticals Inc.’s earnings expectations2026 Momentum & High Return Stock Watch Alerts - baoquankhu1.vn
Can KalVista Pharmaceuticals Inc withstand a market correctionGold Moves & Reliable Intraday Trade Alerts - baoquankhu1.vn
Aug Macro: How does KalVista Pharmaceuticals Inc perform in inflationary periodsWatch List & Stock Market Timing Techniques - baoquankhu1.vn
Tudor Investment Corp ET AL Makes New $24.36 Million Investment in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Macro Review: Is KalVista Pharmaceuticals Inc forming higher highs and higher lows2026 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema L - PharmiWeb.com
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference - The AI Journal
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New EKTERLY (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference - FinanzNachrichten.de
Retail Trends: How does KalVista Pharmaceuticals Inc perform in inflationary periodsMarket Volume Summary & Risk Controlled Daily Trade Plans - baoquankhu1.vn
KalVista Pharmaceuticals Inc Stock Warning Signs - GuruFocus
KalVista Pharmaceuticals (HAM:4XC1) Sale Of Business : €0.00 Mil (TTM As of Jul. 2025) - GuruFocus
KalVista Pharmaceuticals (HAM:4XC1) Cyclically Adjusted PS Ratio : (As of Mar. 19, 2026) - GuruFocus
KalVista Pharmaceuticals Inc Stock Operating Data - GuruFocus
How (KALV) Movements Inform Risk Allocation Models - Stock Traders Daily
KalVista Pharmaceuticals Inc (HAM:4XC1)Valuation Measures & Financial Statistics - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) Stock Earnings Transcripts - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) Dividend - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) Stock HoldersInstitutional & Insider Ownership - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) DCF Valuation - GuruFocus
KalVista Pharmaceuticals Inc (HAM:4XC1) Stock Price, Trades & News - GuruFocus
Kalvista Pharmaceuticals To Report Eight Months Fiscal Year 2025 Financial Results And Provide Corporate Update On March 25, 2026 - TradingView
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet - MSN
Breakout Watch: Is KalVista Pharmaceuticals Inc subject to activist investor interestQuarterly Growth Report & Technical Pattern Alert System - baoquankhu1.vn
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corpo - PharmiWeb.com
Kalvista Pharmaceuticals Inc (KALV) announced that it will release its financial results for the first eight months of fiscal year 2025 on March 25, 2026, and will also provide an update on the latest developments in the company's business. - Bitget
KalVista Pharmaceuticals Inc (HAM:4XC1) Stock News, Headlines & Updates - GuruFocus
Gap Down: Should I hold or sell KalVista Pharmaceuticals Inc now2026 Volume & Fast Entry High Yield Tips - baoquankhu1.vn
KalVista Pharmaceuticals (KALV) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Equities Analysts Issue Forecasts for KALV Q2 Earnings - MarketBeat
Boxer Capital Management LLC Decreases Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Suvretta Capital Management LLC Reduces Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
What is HC Wainwright's Estimate for KALV FY2027 Earnings? - MarketBeat
Hedge Fund Bets: Can KalVista Pharmaceuticals Inc deliver consistent dividendsShort Setup & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
KalVista Pharmaceuticals executive Nicole Sweeny honored as MMM Women of Distinction award recipient - Traders Union
KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - MSN
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):